A Phase II Safety and Efficacy Study of the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Pazopanib in Patients with Metastatic Urothelial Cancer

  • R. Pili
  • , R. Qin
  • , P.J. Flynn
  • , J. Picas
  • , Michael Millward
  • , W.M. Ho
  • , H. Pitot
  • , W. Tan
  • , K.M. Miles
  • , C. Erlichman
  • , U. Vaishampayan

    Research output: Contribution to journalArticlepeer-review

    60 Citations (Scopus)
    Original languageEnglish
    Pages (from-to)477-88
    JournalClinical Genitourinary Cancer
    Volume11
    Issue number4
    DOIs
    Publication statusPublished - 2014

    Cite this